GSK announces succession plan for cfo

Simon Dingemans joins from Goldman Sachs

Simon Dingemans has been named as chief financial officer designate and executive director of GlaxoSmithKline (GSK) from 4 January 2011. He will succeed Julian Heslop, who is to retire as chief financial officer and executive director of the company at the end of March 2011.

Dingemans joins the pharmaceutical firm from Goldman Sachs where he is currently managing director and partner. He has more than 25 years’ experience in investment banking, including most recently as leader of Goldman Sachs' European M&A business and before that as head of UK Investment Banking. During this time he has built relationships and offered strategic advice across multiple industry sectors, including pharmaceuticals and consumer healthcare.

Dingemans has worked closely with GSK for many years, most recently helping to establish ViiV Healthcare, a specialist HIV company.

Andrew Witty, chief executive of GSK, said: ‘Simon's appointment as cfo reflects the need for GSK to operate with both creativity and continued financial discipline. He will also be responsible for delivering cost savings from our global restructuring programme and implementing further measures to simplify our operational model.’

You may also like

Finance

Moderna partners with Recordati to commercialise propionic acidemia mRNA therapy

The pair have entered a strategic collaboration to advance and globally commercialise its investigational propionic acidemia treatment mRNA-3927, with Moderna leading clinical development and manufacturing and Recordati responsible for worldwide commercialisation
Finance

AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration

The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery capabilities and injectable dosing technology
Finance

Ardena divests Södertälje API site to Nanologica

The divestment of the company's drug substance manufacturing site in Sweden to Nanologica is part of a strategic move to focus investment on specialised CDMO capabilities supporting precision medicines
Finance

Global consortium launches to accelerate antibiotic discovery

The $60m consortium backed by the Gates Foundation, Novo Nordisk Foundation and Wellcome aims to speed the discovery of next-generation antibiotics to tackle the growing threat of antimicrobial resistance
Research & Development

EMBO Installation Grant supports new genome editing lab at Vilnius University

Dr C. Patinios Awarded EMBO Installation Grant to advance genome editing research in Lithuania
Manufacturing

Sharp Services invests more than €20m to expand injectables packaging capacity at its European facilities

Expansion includes significant cold chain warehouse capacity to support injectable formats
Finance

Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035

Syngene International, a global contract research, development, and manufacturing organisation (CRDMO), announces the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035
Subscribe now